Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
6 papers
Recent·Most cited
J. Bhin, M. Paes Dias, E. Gogola, F. Rolfs, S. R. Piersma, R. de Bruijn, J. de Ruiter, B. van den Broek, A. Duarte, W. Sol, I. van der Heijden, L. Bakker, T. S. Kaiponen, C. Lieftink, B. Morris, , J. Jonkers
bioRxiv · Sep 7, 2022Cancer Biology
K. J. Ciecielski, A. Mulero-Sanchez, A. Berninger, L. R. Canas, A. Bosma, K. Gorgulu, N. Wu, K. N. Diakopoulos, E. Kaya-Aksoy, D. A. Ruess, D. Kabacaoglu, F. Schmidt, L. Heinemann, Y. Fan, B. Thijssen, , S. Mainardi
This paper investigates the combination of SHP2 and ERK inhibition as a treatment for KRAS-driven pancreatic ductal adenocarcinoma, showing synergistic anticancer effects and tumor regression in mouse models.
bioRxiv · Dec 14, 2021 · PreprintCancer Biology
N. A. Schubert, S. R. van Hooff, L. Schild, K. Ober, M. Hortensius, K. van den Handel, A. H. W. Essing, B. Koopmans, M. Boeije, N. Proost, M. van de Ven, S. Jansky, S. A. Stainczyk, U. H. Toprak, F. Westermann, , M. L. van den Boogaard
bioRxiv · Oct 27, 2021 · PreprintCancer Biology
Z. Pogacar, J. L. Johnson, L. Krenning, G. De Conti, C. Lieftink, A. Velds, L. Wardak, F. Jochems, K. Groot, A. Schepers, L. Wang, J.-Y. Song, M. van de Ven, O. van Tellingen, R. H. Medema, , R. Leite de Oliveira
The paper identifies that combining indisulam with palbociclib enhances senescence in cancer cells by inhibiting CDK2 kinase activity.
bioRxiv · Oct 18, 2021Cancer Biology
J. B. Post, N. Hami, J. Lohuis, M. van de Ven, R. de Korte-Grimmerink, C. S. Stangl, E. Stelloo, I. Verlaan, J. van Rheenen, H. J. G. Snippert
This study uses CRISPR to generate CRC organoids with different RAS pathway mutations, revealing distinct drug responses and growth patterns.
bioRxiv · Nov 29, 2019 · PreprintCancer Biology
M. Barazas, A. Gasparini, Y. Huang, A. Kucukosmanoglu, S. Annunziato, P. Bouwman, W. Sol, A. Kersbergen, N. Proost, M. van de Ven, J. Jonkers, G. Borst, S. Rottenberg
This study identifies radiotherapy as a therapeutic target for BRCA1-deficient tumors that have developed resistance to PARP inhibitors through 53BP1 pathway inactivation.
bioRxiv · Jul 17, 2018Cancer Biology